CeriBell (NASDAQ:CBLL) Receives Average Rating of "Buy" from Brokerages

CeriBell (NASDAQ:CBLL - Get Free Report) has been assigned an average rating of "Buy" from the six research firms that are currently covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $32.60.

A number of research firms have recently weighed in on CBLL. TD Cowen upped their price objective on CeriBell from $31.00 to $36.00 and gave the stock a "buy" rating in a research note on Monday, December 9th. Canaccord Genuity Group restated a "buy" rating and issued a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th.

CeriBell Stock Performance

Shares of CBLL stock traded down $0.12 during trading hours on Monday, hitting $23.11. 4,418 shares of the company's stock traded hands, compared to its average volume of 201,366. The stock has a fifty day moving average price of $22.85. CeriBell has a 12-month low of $18.69 and a 12-month high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The business had revenue of $18.53 million during the quarter, compared to analyst estimates of $17.55 million. As a group, sell-side analysts forecast that CeriBell will post -2.46 earnings per share for the current fiscal year.

Remove Ads

Institutional Trading of CeriBell

Several hedge funds have recently modified their holdings of the company. Rhumbline Advisers bought a new stake in CeriBell in the fourth quarter worth $320,000. Bank of New York Mellon Corp purchased a new position in shares of CeriBell in the 4th quarter worth $628,000. Charles Schwab Investment Management Inc. bought a new stake in shares of CeriBell in the 4th quarter worth about $2,500,000. PNC Financial Services Group Inc. purchased a new stake in shares of CeriBell during the 4th quarter valued at about $47,000. Finally, Vanguard Group Inc. bought a new position in shares of CeriBell in the 4th quarter valued at about $18,015,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.